USA - NASDAQ:CELU - US1511902041 - Common Stock
The current stock price of CELU is 1.96 USD. In the past month the price decreased by -10.81%. In the past year, price decreased by -21.12%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.82 | 408.29B | ||
AMGN | AMGEN INC | 13.73 | 161.20B | ||
GILD | GILEAD SCIENCES INC | 15.95 | 153.18B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.59 | 106.80B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.04B | ||
REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
ARGX | ARGENX SE - ADR | 92.05 | 52.20B | ||
INSM | INSMED INC | N/A | 34.73B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.15 | 35.01B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 26.47B | ||
BIIB | BIOGEN INC | 9.19 | 21.56B |
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
CELULARITY INC-A
170 Park Ave
Florham Park NEW JERSEY US
Employees: 120
Phone: 19087682170
The current stock price of CELU is 1.96 USD. The price decreased by -1.01% in the last trading session.
The exchange symbol of CELULARITY INC-A is CELU and it is listed on the Nasdaq exchange.
CELU stock is listed on the Nasdaq exchange.
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 212.24% is expected in the next year compared to the current price of 1.96. Check the CELULARITY INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CELULARITY INC-A (CELU) has a market capitalization of 52.31M USD. This makes CELU a Micro Cap stock.
CELULARITY INC-A (CELU) currently has 120 employees.
CELULARITY INC-A (CELU) has a resistance level at 2.1. Check the full technical report for a detailed analysis of CELU support and resistance levels.
The Revenue of CELULARITY INC-A (CELU) is expected to grow by 27.37% in the next year. Check the estimates tab for more information on the CELU EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CELU does not pay a dividend.
CELULARITY INC-A (CELU) will report earnings on 2025-12-04.
CELULARITY INC-A (CELU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.19).
The outstanding short interest for CELULARITY INC-A (CELU) is 9.19% of its float. Check the ownership tab for more information on the CELU short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CELU. CELU may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CELU reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS increased by 44.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -61.3% | ||
ROE | N/A | ||
Debt/Equity | N/A |
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 212.24% is expected in the next year compared to the current price of 1.96.
For the next year, analysts expect an EPS growth of -752.63% and a revenue growth 27.37% for CELU